ACE and diabetes mellitus: Although angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers are recommended to reduce the prevalence of ESRD in patients with diabetes, it is well known that patients with diabetes have a high residual risk of ESRD38–40.